Mylan launches generic Frova tablets
CANONSBURG – Mylan N.V. announced Thursday the U.S. launch of Frovatriptan Succinate tablets 2.5 mg, a 2.5 mg. generic version of Endo’s Frova tablets.
Mylan, whose administrative headquarters are in Southpointe, received final approval from the U.S. Food and Drug Administration for the product, which is used to treat acute migraine headaches in adults.
Frovatriptan Succinate Tablets 2.5 mg had U.S. sales of approximately $88.3 million for the 12 months ending March 31, according to IMS Health.